-
Something wrong with this record ?
Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay
P. Barta, M. Volkova, A. Dascalu, D. Spiegelberg, F. Trejtnar, K. Andersson,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Time Factors MeSH
- Epidermal Growth Factor chemistry metabolism MeSH
- ErbB Receptors antagonists & inhibitors chemistry metabolism MeSH
- Antibodies, Monoclonal, Humanized chemistry pharmacology MeSH
- Binding, Competitive drug effects MeSH
- Humans MeSH
- Ligands MeSH
- Antibodies, Monoclonal chemistry pharmacology MeSH
- Tumor Cells, Cultured MeSH
- Substrate Specificity MeSH
- Transforming Growth Factor alpha chemistry metabolism MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
INTRODUCTION: Competitive binding assays can be used to decipher not only the binding kinetics of studied ligands but also the binding site preference. Such assays are an essential step in the characterization of radioligands. However, the currently used competition assays require high concentrations of usually expensive ligands and still provide only binding site preference. By employing the time-resolved competition assay presented in this paper, binding characteristics including binding site preference can be obtained using less ligand. METHODS: To demonstrate the appropriateness of the time-resolved competition assay, we developed an assay in which the ligand binding was interrupted with a competitor. Experiments were performed on human carcinoma cell lines expressing epidermal growth factor receptor (EGFR). The targeting of the receptor was performed with radio-iodinated epidermal growth factor (EGF). The employed competitors involved either natural ligand transforming growth factor alpha (TGF-α) or anti-EGFR antibodies cetuximab and panitumumab targeting the same EGFR domain. RESULTS: Radio-iodinated EGF bound to EGFR was displaced with either low concentrations of cetuximab or high concentrations of panitumumab. In the case of TGF-α, we observed no competitive displacement of bound EGF at either high or low concentrations. When comparing the time-resolved competition assay with a manual competition assay, the resulting data of measured inhibition constants were in agreement. DISCUSSION: The results summarised in this study confirm the appropriateness of the time-resolved competition assay for assessing ligand binding properties. The assay has the potential to complement or replace conventional competition assays for determining binding site preference in the future.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15023181
- 003
- CZ-PrNML
- 005
- 20150730095141.0
- 007
- ta
- 008
- 150709s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.vascn.2014.07.006 $2 doi
- 035 __
- $a (PubMed)25084055
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Barta, Pavel $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Charles University in Prague, Hyerovskeho 1203, 50005 Hradec Kralove, Czech Republic. Electronic address: pavel.barta@faf.cuni.cz.
- 245 10
- $a Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay / $c P. Barta, M. Volkova, A. Dascalu, D. Spiegelberg, F. Trejtnar, K. Andersson,
- 520 9_
- $a INTRODUCTION: Competitive binding assays can be used to decipher not only the binding kinetics of studied ligands but also the binding site preference. Such assays are an essential step in the characterization of radioligands. However, the currently used competition assays require high concentrations of usually expensive ligands and still provide only binding site preference. By employing the time-resolved competition assay presented in this paper, binding characteristics including binding site preference can be obtained using less ligand. METHODS: To demonstrate the appropriateness of the time-resolved competition assay, we developed an assay in which the ligand binding was interrupted with a competitor. Experiments were performed on human carcinoma cell lines expressing epidermal growth factor receptor (EGFR). The targeting of the receptor was performed with radio-iodinated epidermal growth factor (EGF). The employed competitors involved either natural ligand transforming growth factor alpha (TGF-α) or anti-EGFR antibodies cetuximab and panitumumab targeting the same EGFR domain. RESULTS: Radio-iodinated EGF bound to EGFR was displaced with either low concentrations of cetuximab or high concentrations of panitumumab. In the case of TGF-α, we observed no competitive displacement of bound EGF at either high or low concentrations. When comparing the time-resolved competition assay with a manual competition assay, the resulting data of measured inhibition constants were in agreement. DISCUSSION: The results summarised in this study confirm the appropriateness of the time-resolved competition assay for assessing ligand binding properties. The assay has the potential to complement or replace conventional competition assays for determining binding site preference in the future.
- 650 _2
- $a monoklonální protilátky $x chemie $x farmakologie $7 D000911
- 650 _2
- $a humanizované monoklonální protilátky $x chemie $x farmakologie $7 D061067
- 650 _2
- $a kompetitivní vazba $x účinky léků $7 D001667
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a epidermální růstový faktor $x chemie $x metabolismus $7 D004815
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a erbB receptory $x antagonisté a inhibitory $x chemie $x metabolismus $7 D066246
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a substrátová specifita $7 D013379
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a transformující růstový faktor alfa $x chemie $x metabolismus $7 D016211
- 650 _2
- $a nádorové buňky kultivované $7 D014407
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Volkova, Marie $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Charles University in Prague, Hyerovskeho 1203, 50005 Hradec Kralove, Czech Republic.
- 700 1_
- $a Dascalu, Adrian $u Rudbeck Laboratory/BMS, Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Dag Hammarskjölds väg 20, 75185, Uppsala, Sweden.
- 700 1_
- $a Spiegelberg, Diana $u Rudbeck Laboratory/BMS, Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Dag Hammarskjölds väg 20, 75185, Uppsala, Sweden.
- 700 1_
- $a Trejtnar, Frantisek $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Charles University in Prague, Hyerovskeho 1203, 50005 Hradec Kralove, Czech Republic.
- 700 1_
- $a Andersson, Karl $u Rudbeck Laboratory/BMS, Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Dag Hammarskjölds väg 20, 75185, Uppsala, Sweden; Ridgeview Instruments AB, Skillsta 4, 74020 Vänge, Sweden. $7 gn_A_00006202
- 773 0_
- $w MED00002898 $t Journal of pharmacological and toxicological methods $x 1873-488X $g Roč. 70, č. 2 (2014), s. 145-51
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25084055 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20150730095228 $b ABA008
- 999 __
- $a ok $b bmc $g 1083519 $s 906174
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 70 $c 2 $d 145-51 $i 1873-488X $m Journal of pharmacological and toxicological methods $n J Pharmacol Toxicol Methods $x MED00002898
- LZP __
- $a Pubmed-20150709